We deliver economical and high-value generic drugs with assured quality and reliable product information.

In Japan, the government target of achieving a usage rate of over 80% for generic drugs on a quantity basis has been met, and the market has reached a mature stage. However, the business environment is becoming increasingly challenging due to annual NHI drug price revisions. Additionally, in recent years, quality issues at other companies have heightened societal demands for quality assurance and stable supply from companies handling generic drugs.

Under these circumstances, our company, which consistently handles development, manufacturing, and sales of generic drugs, is working on developing generic drugs that reflect the needs of patients and healthcare professionals. At the same time, we are strengthening various initiatives to further improve product quality and ensure stable supply.

We contribute to speedy diagnosis and planning of treatment through POCT (Point of Care Testing, clinical tests conducted at medical institutions).

Our company handles clinical testing kits and agents in the fields of allergic diseases and lifestyle-related diseases. Among our products, the “DropScreen,” an allergy screening kit and reagent developed in-house, launched in 2020, is a groundbreaking product that can measure 41 types of allergens in a short time with a small blood sample. It has been installed by many hospitals and clinics in Japan. We are also planning to expand overseas, working on the development of reagents tailored to each region as well as the selection of partners.

Continuously develop and monetize groundbreaking new drugs based on our proprietary technologies and know-how, including alkalization therapy.

We are working to develop new breakthrough drugs to benefit patients from diseases for which currently there are no appropriate therapeutic drugs. In addition to leveraging the alkalization therapy technology and knowledge that we have cultivated over many years, we are also actively working on alliances with other companies and research institutions to further expand our development pipeline and incorporate rapidly evolving digital technologies such as AI into drug discovery methods.

Supporting a comfortable lifestyle.

We handle a diverse array of healthcare products, including health foods, cosmetics, and various types of creams, classified as quasi-drugs.

As consumer demand for self-medication increases, we leverage our trust and development expertise as an ethical pharmaceutical manufacturer to provide high-value products that supports your daily life.